News & Events

Meeting Reports 2003

Assessment of Success of the R03 Program

Presented at the Advisory Council Meeting of the NIAMS on May 22, 2003 (historical)

PDF Version of this Document

Background:

  • Purpose:
    • The R03 program was begun because of a lack of start-up funds for new investigators
      - Mentioned in many venues
  • Phasing:
    • A decision was made to gradually phase in the program over several years. First via annual RFA soliciations and then through Program Announcements
  • Questions:
    • Has the R03 program been successful?
    • Should the R03 program be altered in any way?

Eligibility Criteria

  • Eligible:
    • Former and current recipients of:
      -Small research grants (R03s)
      -Academic Research Enhancement Awards (AREA) (R15)
      -Mentored Clinical Scientist Development Awards (K08)
      -Mentored Research Scientist Development Awards (K01)
      -Shannon Awards (R55)
      -Individual (F32) or Institutional (T32) National Research Service Award (NRSA) training support
  • Non-Eligible:
    • Current and previous holders of R01s
    • Current and previous holders of R29s
    • Principal Investigators (PIs) of research subprojects of Research Program Projects (P01) and Centers (P50 and P60)
    • PIs with support from NSF or VA

History of the R03 Program
Receipt Dates

  • Requests for Applications -
    • March 18, 1997 (AR-97-001)
    • April 29, 1998 (AR-98-002)
    • January 22, 1999 (AR-99-001)
  • Program Announcements -
    • 3 times/year in 1999, 2000 and 2001 (PAR-99-099)
    • 3 times/year in 2002 and 2003 (PAR-02-030)

Some Evaluation Questions

  • What is the purpose of the program?
    • Small projects? Start-up funds?
  • When is the appropriate time to conduct the evaluation?
    • How long after completion of the R03?
  • How should "success" be defined?
    • Receipt of a subsequent R01?
    • Taking a position in industry?
    • Proving that a research idea is not feasible?
  • What is the most appropriate control group?
  • Are there differences in program distribution for the R03 awards?
  • A CAVEAT: Some of the data in subsequent slides may differ slightly from official budget office data due to variations in co-funding

General Facts

  • Only data from the first three competitions were analyzed
  • There were 323 applications for the first three competitions and 297 applicants

R03 Awards

  • From the 97-001 competition:
    • 153 R03 applications
    • 26 awards (17.0% success rate)
  • From the 98-002 competition:
    • 94 R03 applications
    • 24 awards (25.5% success rate)
  • From the 99-001 competition:
    • 76 R03 applications
    • 26 awards (34.2% success rate)
  • From the 99-099 competition:
    • 316 R03 applications
    • 71 awards (22.5% success rate)

Award Statistics

bar chart comparing number of applications to number of awards

Subsequent R01 Awards

  • From the 97-001 competition:
    • 42% of NIAMS R03 awardees had a subsequent R01
    • 17% of unsuccessful R03 applicants had a subsequent R01
    • 25% of all applicants had a subsequent R01
  • From the 98-002 competition:
    • 31% of NIAMS R03 awardees had a subsequent R01
    • 12% of unsuccessful R03 applicants had a subsequent R01
    • 26% of all applicants had a subsequent R01
  • From the 99-001 competition:
    • 24% of NIAMS R03 awardees had a subsequent R01
    • 7% of unsuccessful R03 applicants had a subsequent R01
    • 18% of all applicants had a subsequent R01

General Conclusions

  • R03 awardees were more likely to obtain a subsequent R01 award than unsuccessful applicants
  • The greater the amount of time that has passed since the R03 award the more likely the chance of having a R01

Does the branch make a difference in the success rate for obtaining a R03?

R03 Success Rate by Branch

Success Rate By Branch for Applications to that Branch Per RFA

Branch
RFA 97-001
RFA 98-002
RFA 99-001
All RFAs
Rheumatic
13.6% (9/57)
26.9% (8/38)
43.8% (10/25)
22.5% (27/120)
Muscle Biol.
0.0% (0/9)
37.5% (3/8)
22.2% (2/9)
19.2% (5/26)
Skin
25.0% (8/32)
37.5% (3/8)
50.0% (3/6)
30.4% (14/46)
Musculoskeletal
13.3% (9/55)
15.0% (10/40)
33.3% (10/35)
22.1% (29/131)